Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia.
SARS-CoV-2 vaccination
bone marrow failure
severe aplastic anaemia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
26
08
2022
received:
25
07
2022
accepted:
30
08
2022
pubmed:
22
9
2022
medline:
25
11
2022
entrez:
21
9
2022
Statut:
ppublish
Résumé
Patients with severe aplastic anaemia (SAA) are often not vaccinated against viruses due to concerns of ineffective protective antibody response and potential for pathogenic global immune system activation, leading to relapse. We evaluated the impact of COVID-19 vaccination on haematological indices and disease status and characterized the humoural and cellular responses to vaccination in 50 SAA patients, who were previously treated with immunosuppressive therapy (IST). There was no significant difference in haemoglobin (p = 0.52), platelet count (p = 0.67), absolute lymphocyte (p = 0.42) and neutrophil (p = 0.98) counts prior to and after completion of vaccination series. Relapse after vaccination, defined as a progressive decline in counts requiring treatment, occurred in three patients (6%). Humoural response was detectable in 90% (28/31) of cases by reduction in an in-vitro Angiotensin II Converting Enzyme (ACE2) binding and neutralization assay, even in patients receiving ciclosporin (10/11, 90.1%). Comparison of spike-specific T-cell responses in 27 SAA patients and 10 control subjects revealed qualitatively similar CD4
Identifiants
pubmed: 36128909
doi: 10.1111/bjh.18456
pmc: PMC9538485
doi:
Substances chimiques
Cyclosporine
83HN0GTJ6D
COVID-19 Vaccines
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
679-687Informations de copyright
Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
Références
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92.
Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643-56.
Smith JN, Kanwar VS, MacNamara KC. Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Front Immunol. 2016;7:330.
Omokaro SO, Desierto MJ, Eckhaus MA, Ellison FM, Chen J, Young NS. Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model. J Immunol. 2009;182(6):3414-22.
Liu CY, Fu R, Wang HQ, Li LJ, Liu H, Guan J, et al. Fas/FasL in the immune pathogenesis of severe aplastic anemia. Genet Mol Res. 2014;13(2):4083-8.
Avenoso D, Marsh JC, Potter V, Pagliuca A, Slade S, Dignan F, et al. SARS-CoV-2 infection in aplastic anemia. Haematologica. 2022;107(2):541-3.
Paton C, Mathews L, Groarke EM, Rios O, Lotter J, Patel BA, et al. COVID-19 infection in patients with severe aplastic anaemia. Br J Haematol. 2021;193(5):902-5.
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
Fritch JE, Losole T, Leyden L, Bedrnicek J, Perry DA, Acquazzino MA, et al. Acquired aplastic anemia in immunocompetent pediatric patients with asymptomatic COVID-19 infection: a case series. Blood. 2021;138:1103.
Lee NC, Patel B, Etra A, Bat T, Ibrahim IF, Vusirikala M, et al. SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia. Blood Adv. 2022;6(13):3840-3.
Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138(14):1278-81.
Maillard A, Redjoul R, Klemencie M, Labussière Wallet H, Le Bourgeois A, d'Aveni M, et al. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood. 2022;139(1):134-7.
Fattizzo B, Bortolotti M, Giannotta JA, Consonni D, Cantoni S, Barcellini W. Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures. Sci Rep. 2022;12(1):1-7.
Walter J, Kricheldorf K, Isfort S, Brümmendorf TH, Panse J, Beier F. Antibody titers after SARS-CoV-2 mRNA vaccination in patients with aplastic anemia-a single-center study. Eur J Haematol. 2022;108(6):528-31.
Pike A, McKinley C, Forrest B, Scott R, Charlton E, Scott E, et al. COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. Lancet Haematol. 2022;9(8):e553-6.
Le Bert N, Tan AT, Kunasegaran K, Tham CY, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-62.
Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162-3.
Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79(2):167-74.
Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, et al. Acquired aplastic anemia following SARS-CoV-2 vaccination. Eur J Haematol. 2022;109(2):186-94.
Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372-7.
Dayam RM, Law JC, Goetgebuer RL, Chao GY, Abe KT, Sutton M, et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases. JCI Insight. 2022;7(11):e159721.
Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728.